Skip to main content
Erschienen in: Der Anaesthesist 11/2012

01.11.2012 | Originalien

Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™

verfasst von: M. Casutt, M.D., C. Konrad, G. Schuepfer

Erschienen in: Die Anaesthesiologie | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

This study investigated the influence of the oral direct inhibitor of factor Xa rivaroxaban on blood coagulation measured by rotation thrombelastometry ROTEM™. Blood was obtained from 11 healthy male volunteers before and 2.5 h after oral administration of 10 mg rivaroxaban. In addition to standard coagulation tests clot formation was measured by ROTEM™ analyzing extrinsic (Extem) and intrinsic thrombelastometry (Intem). Significant differences to the baseline values were found in the Extem clotting time (Extem-CT, 58 ± 9 s and 87 ± 17 s, p < 0.01), Intem-CT (194 ± 26 s and 239 ± 43 s; p = 0.02), prothrombin time (PT, 86 ± 9% and 67 ± 7%; p < 0.01) and activated partial thromboplastin time (aPTT, 28 ± 1 s and 35 ± 2 s; p < 0.01). There was a low correlation between Extem-CT and PT as well as between Intem-CT and aPTT before and after rivaroxaban intake. The receiver operating characteristic curve (ROC) analysis determined aPTT to be the most appropriate parameter for the prediction of rivaroxaban-induced anticoagulation, Intem-CT and Extem-CT proved to be moderate tests and PT had no significance in the prediction of rivaroxaban-induced anticoagulation. Of utmost clinical importance was the fact that rivaroxaban treated patients could still show normal ROTEM™ values. Thus, ROTEM™ cannot be a suitable test method to exclude inhibition of blood coagulation by rivaroxaban.
Literatur
1.
Zurück zum Zitat Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510PubMedCrossRef Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510PubMedCrossRef
2.
Zurück zum Zitat c et al (2010) Effects on coagulation of balanced (130/0.42) and non-balanced (130/0.4) hydroxyethyl starch or gelatin compared with balanced Ringer’s solution: an in vitro study using two different viscoelastic coagulation tests ROTEMTM and SONOCLOTTM. Br J Anaesth 105:273–281CrossRef c et al (2010) Effects on coagulation of balanced (130/0.42) and non-balanced (130/0.4) hydroxyethyl starch or gelatin compared with balanced Ringer’s solution: an in vitro study using two different viscoelastic coagulation tests ROTEMTM and SONOCLOTTM. Br J Anaesth 105:273–281CrossRef
3.
Zurück zum Zitat Cohen AT, Spiro TE, Buller HR et al (2011) Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 31:407–416PubMedCrossRef Cohen AT, Spiro TE, Buller HR et al (2011) Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 31:407–416PubMedCrossRef
4.
Zurück zum Zitat Engstrom M, Rundgren M, Schott U (2010) An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 54:86–91PubMedCrossRef Engstrom M, Rundgren M, Schott U (2010) An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 54:86–91PubMedCrossRef
5.
Zurück zum Zitat Eriksson BI, Borris LC, Dahl OE et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685–693PubMedCrossRef Eriksson BI, Borris LC, Dahl OE et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685–693PubMedCrossRef
6.
Zurück zum Zitat Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef
7.
Zurück zum Zitat Ganter MT, Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 106:1366–1375PubMedCrossRef Ganter MT, Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 106:1366–1375PubMedCrossRef
8.
Zurück zum Zitat Gibson CM, Mega JL, Burton p et al (2011) Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 161:815–821 e816PubMedCrossRef Gibson CM, Mega JL, Burton p et al (2011) Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 161:815–821 e816PubMedCrossRef
9.
Zurück zum Zitat Herbstreit F, Winter EM, Peters J, Hartmann M (2010) Monitoring of haemostasis in liver transplantation: comparison of laboratory based and point of care tests. Anaesthesia 65:44–49PubMedCrossRef Herbstreit F, Winter EM, Peters J, Hartmann M (2010) Monitoring of haemostasis in liver transplantation: comparison of laboratory based and point of care tests. Anaesthesia 65:44–49PubMedCrossRef
10.
Zurück zum Zitat Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef
11.
Zurück zum Zitat Kubitza D, Becka M, Voith B et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421PubMedCrossRef Kubitza D, Becka M, Voith B et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421PubMedCrossRef
12.
Zurück zum Zitat Kubitza D, Haas S (2006) Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 15:843–855PubMedCrossRef Kubitza D, Haas S (2006) Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 15:843–855PubMedCrossRef
13.
Zurück zum Zitat Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRef Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRef
14.
Zurück zum Zitat Laux V, Perzborn E, Heitmeier S et al (2009) Direct inhibitors of coagulation proteins—the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 102:892–899PubMed Laux V, Perzborn E, Heitmeier S et al (2009) Direct inhibitors of coagulation proteins—the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 102:892–899PubMed
15.
Zurück zum Zitat Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38PubMedCrossRef Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38PubMedCrossRef
16.
Zurück zum Zitat Nilsson CU, Engstrom M (2007) Monitoring fondaparinux with the Sonoclot. Blood Coagul Fibrinolysis 18:619–622PubMedCrossRef Nilsson CU, Engstrom M (2007) Monitoring fondaparinux with the Sonoclot. Blood Coagul Fibrinolysis 18:619–622PubMedCrossRef
17.
Zurück zum Zitat Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef
18.
Zurück zum Zitat ROCKET-AF-Study-Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159:340–347 e341CrossRef ROCKET-AF-Study-Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159:340–347 e341CrossRef
19.
Zurück zum Zitat Roehrig S, Straub A, Pohlmann J et al (2005) Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900–5908PubMedCrossRef Roehrig S, Straub A, Pohlmann J et al (2005) Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900–5908PubMedCrossRef
20.
Zurück zum Zitat Rugeri L, Levrat A, David JS et al (2007) Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 5:289–295PubMedCrossRef Rugeri L, Levrat A, David JS et al (2007) Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 5:289–295PubMedCrossRef
21.
Zurück zum Zitat Samama MM, Gerotziafas GT (2010) Newer anticoagulants in 2009. J Thromb Thrombolysis 29:92–104PubMedCrossRef Samama MM, Gerotziafas GT (2010) Newer anticoagulants in 2009. J Thromb Thrombolysis 29:92–104PubMedCrossRef
22.
Zurück zum Zitat Samama MM, Martinoli JL, LeFlem L et al (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825PubMedCrossRef Samama MM, Martinoli JL, LeFlem L et al (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825PubMedCrossRef
23.
Zurück zum Zitat Turpie AG (2007) Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27:1238–1247PubMedCrossRef Turpie AG (2007) Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27:1238–1247PubMedCrossRef
24.
Zurück zum Zitat Turpie AG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRef Turpie AG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRef
Metadaten
Titel
Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™
verfasst von
M. Casutt, M.D.
C. Konrad
G. Schuepfer
Publikationsdatum
01.11.2012
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Anaesthesiologie / Ausgabe 11/2012
Print ISSN: 2731-6858
Elektronische ISSN: 2731-6866
DOI
https://doi.org/10.1007/s00101-012-2091-4

Weitere Artikel der Ausgabe 11/2012

Der Anaesthesist 11/2012 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.